Clinical Trial Update: Mechanism of Action of Ocrelizumab in Multiple Sclerosis

View source ↗

Summary

A clinical trial update outlines the mechanism of action of ocrelizumab in multiple sclerosis and notes that trial results have been posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: University of Chicago | Conditions: Multiple Sclerosis, Immune System Diseases | Status: COMPLETED | Results posted: 2025-02-21